This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Prostheses/ Implants  • Vitreoretinal Surgery  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Anat Galor, MD; Ron Margolis, MD; Peter K. Kaiser, MD; Careen Y. Lowder, MD, PhD

Arch Ophthalmol. 2007;125(6):836-838.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The fluocinolone acetonide implant (Retisert; Bausch & Lomb, Rochester, NY) is a sustained-release, intravitreal steroid implant developed to treat chronic noninfectious uveitis.¹ Two, 3-year, phase 3, randomized, multicenter clinical trials have demonstrated a statistically significant decrease in the recurrence of uveitis and the need for additional corticosteroids or other immunosuppressive agents after implantation.²

During these studies, 50% to 90% of patients experienced an adverse event after implantation, most commonly cataract formation and increased intraocular pressure.² Within 2 years of implantation, nearly 100% of phakic eyes required cataract surgery and one third of patients required a glaucoma surgical procedure. Other adverse events included ptosis, eyelid edema, conjunctival hemorrhage, chemosis, corneal edema, vitreous opacities, vitreous hemorrhage, macular edema, retinal hemorrhage, hypotony, and choroidal detachment.² We describe 4 patients with an adverse ocular event not previously described after . . . [Full Text of this Article]

Methods


Results
Case 1

Case 2

Case 3

Case 4

Comment

AUTHOR INFORMATION